These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27748335)

  • 41. Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?
    Çavuş B; Akyuz F; İliaz R; Atasoy A; Akyuz U; Demir K; Besisik F; Kaymakoglu S
    Int J Immunopathol Pharmacol; 2022; 36():3946320221077860. PubMed ID: 35171719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical features of cirrhosis in Japanese patients with type I autoimmune hepatitis.
    Abe K; Katsushima F; Kanno Y; Takahashi A; Yokokawa J; Ohira H; Arinaga T; Ide T; Nishimura J; Inoue M; Seike M; Imazeki F; Yokosuka O; Sata M
    Intern Med; 2012; 51(24):3323-8. PubMed ID: 23257515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis.
    Laschtowitz A; Zachou K; Lygoura V; Pape S; Derben F; Jaeckel E; Oller-Moreno S; Weidemann S; Krech T; Piecha F; Schön G; Liebhoff AM; Al Tarrah M; Heneghan M; Drenth JPH; Dalekos G; Taubert R; Lohse AW; Schramm C
    JHEP Rep; 2021 Aug; 3(4):100321. PubMed ID: 34381983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of risk factors for the development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH prospective study.
    Migita K; Watanabe Y; Jiuchi Y; Nakamura Y; Saito A; Yagura M; Morimoto H; Shimada M; Mita E; Hijioka T; Yamashita H; Takezaki E; Muro T; Sakai H; Nakamuta M; Abiru S; Yano K; Komori A; Yatsuhashi H; Nakamura M; Ishibashi H
    J Gastroenterol; 2011 Jan; 46 Suppl 1():56-62. PubMed ID: 21042923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
    Wolf DC; Bojito L; Facciuto M; Lebovics E
    Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of prednisolone in patients with autoimmune hepatitis.
    Yoneyama K; Honda E; Kogo M; Kiuchi Y; Shibata M; Mitamura K; Inawari M
    Adv Ther; 2006; 23(1):74-91. PubMed ID: 16644609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of autoimmune hepatitis in primary biliary cirrhosis.
    Gossard AA; Lindor KD
    Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autoimmune hepatitis with confluent necrosis indicates severe liver injury but responds well to standard immunosuppressive therapy.
    Sun X; Su Y; Wee A; Liu J; Wang Q; Zhang J; Zhao X; Jia J
    Histol Histopathol; 2024 Jul; 39(7):935-945. PubMed ID: 38126225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
    Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
    Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
    Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autoimmune hepatitis in African Americans: presenting features and response to therapy.
    Lim KN; Casanova RL; Boyer TD; Bruno CJ
    Am J Gastroenterol; 2001 Dec; 96(12):3390-4. PubMed ID: 11774954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis.
    Ozaslan E; Efe C; Akbulut S; Purnak T; Savas B; Erden E; Altiparmak E
    Hepatogastroenterology; 2010; 57(99-100):441-6. PubMed ID: 20698205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis.
    Pape S; Gevers TJG; Belias M; Mustafajev IF; Vrolijk JM; van Hoek B; Bouma G; van Nieuwkerk CMJ; Hartl J; Schramm C; Lohse AW; Taubert R; Jaeckel E; Manns MP; Papp M; Stickel F; Heneghan MA; Drenth JPH
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2068-2075.e2. PubMed ID: 30625402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of ethnicity on the natural history of autoimmune hepatitis.
    Verma S; Torbenson M; Thuluvath PJ
    Hepatology; 2007 Dec; 46(6):1828-35. PubMed ID: 17705297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands.
    van den Brand FF; van Nieuwkerk CMJ; Verwer BJ; de Boer YS; de Boer NKH; Mulder CJJ; Bloemena E; Bakker CM; Vrolijk JM; Drenth JPH; Tan ACITL; Ter Borg F; Ter Borg MJ; van den Hazel SJ; Inderson A; Tushuizen ME; Bouma G
    Aliment Pharmacol Ther; 2018 Oct; 48(7):761-767. PubMed ID: 30109891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study.
    Muratori P; Carbone M; Stangos G; Perini L; Lalanne C; Ronca V; Cazzagon N; Bianchi G; Lenzi M; Floreani A; Invernizzi P; Muratori L
    Dig Liver Dis; 2018 Jul; 50(7):698-702. PubMed ID: 29567415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome after discontinuation of immunosuppression in children with autoimmune hepatitis: a population-based study.
    Deneau M; Book LS; Guthery SL; Jensen MK
    J Pediatr; 2014 Apr; 164(4):714-719.e2. PubMed ID: 24423432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine.
    Nastasio S; Sciveres M; Matarazzo L; Malaventura C; Cirillo F; Riva S; Maggiore G
    Dig Liver Dis; 2019 May; 51(5):712-718. PubMed ID: 30502231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.
    Lüth S; Kanzler S; Frenzel C; Kasper HU; Dienes HP; Schramm C; Galle PR; Herkel J; Lohse AW
    J Clin Gastroenterol; 2009 Jan; 43(1):75-80. PubMed ID: 18769363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.